

References

L-237

1. UPMC University of Pittsburgh Medical Center. ThyroSeq® - Thyroid Cancer Next- Generation Sequencing Panel.
2. CBL P. ThyroSeq® v.2 Next Generation Sequencing.
3. NCCN. National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2017).
4. Valderrabano P, Khazai L, Leon ME, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. *Endocrine-related cancer*. Jan 19 2017.
5. Shrestha RT, Evasovich MR, Amin K, et al. Correlation between histological diagnosis and mutational panel testing of thyroid nodules: A two-year institutional experience. *Thyroid: official journal of the American Thyroid Association*. 2016;26(8):1068-1076.
6. Valderrabano P, Leon ME, Centeno BA, et al. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. *European journal of endocrinology*. 2016;174(5):621-629.